Approval of Syndax’s Revuforj for acute leukemia makes the twice-daily pill the first in a new class of drugs that block a cancer-driving protein called menin. Other companies developing menin inhibitors include Kura Oncology, Biomea Fusion, and Johnson & Johnson subsidiary Janssen.
A company in the burgeoning field of epigenetics has raised about $5 million in debt financing, right on the heels of refiling for an initial public offering. Syndax Pharmaceuticals, a late-stage Massachusetts biotech, postponed an IPO from June but, according to an August 28 filing, still plans to raise $60 million when it goes public. It’s offering […]
Discover the top AI-powered EAP providers for 2026. Compare platforms like Kyan Health and Spring Health on triage speed, global reach, and clinical quality to transform workforce wellbeing.